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Abstract 
Parathyroid carcinoma is a rare disease, which accounts for less than 1% of all case of primary 
hyperparathyroidism and is usually not detected until the time of surgery or thereafter. For 
most patients preoperative staging is not available. A radical excision remains the standard 
management; the place of adjuvant radiotherapy is not well established yet. Local recurrence 
and/or the metastases are unfortunately frequent. The present paper presents an up to date 
review of the literature illustrated by three clinical cases. 
Key  words:  parathyroid  carcinoma,  hypercalcemia,  hyperparathyroidism,  prognosis,  surgery, 
methylene blue, radiotherapy 
Introduction 
Parathyroid carcinoma, a rare endocrine malig-
nancy, accounts for less than 1% of cases of sporadic 
primary  hyperparathyroidism.  Clinical  manifesta-
tions are generally more severe than in common be-
nign  diseases  such  as  parathyroid  adenoma  or  hy-
perplasia. 
When diagnosed, this neoplasm is a solitary le-
sion but anecdotal cases of multiple lesions have been 
described  1, extremely rarely were bilateral parathy-
roid carcinomas reported 2. 
Usually the disease has an indolent but slowly 
progressive course. Most of the patients will die due 
to complications of hypercalcemia, rather than direct 
tumor invasion or metastases. The management of PC 
is difficult in terms of diagnosis, treatment and fol-
low-up. 
The  distinction  between  malignant  and  benign 
lesions  of  the  parathyroid  is  difficult,  even  with  a 
histopathological  examination.  For  most  patients 
preoperative  staging  is  not  available.  Intraoperative 
findings are important: the surgeon has to distinguish 
between an adenomatous disease and a carcinoma  3. 
A radical excision remains the standard management; 
the place of adjuvant radiotherapy is not well estab-
lished yet. 
Local  recurrence  and/or  metastases  are  unfor-
tunately frequent.  
We present here a review focused on the most 
recent advances in parathyroid carcinoma illustrated 
by three patients treated at our institution. 
Clinical presentation  
Parathyroid carcinomas, a rare entity, accounts 
for less than 1 % 4,5 of all cases of primary hyperpara-
thyroidism. A higher incidence has been reported in 
Japan and Italy where it rises up to 5-5,2%. 6,7 
It is habitually a  sporadic disease, but familial 
cases have been described. 
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Parathyroid  carcinoma  occurs  equally  in  men 
and  women,  while  benign  parathyroid  disease  pre-
dominates in women by a ratio of 3-4:1.  
The average age of diagnosis is the fourth decade 
of life whereas for benign adenomas the average age 
is  thirty  8.  The  3  patients  treated  at  our  institution 
were respectively 35, 58, 76 years old, 2 women and 1 
man 
Paratyhyroid carcinomas have been described in 
15%  of  hyperparathyroidism-jaw  tumor  (HPT-JT) 
syndrome, a rare autosomal disorder. In HPT-JT, os-
sifying fibromas of the maxilla and mandible are seen 
in 30 % of cases9. Less commonly, kidney lesions in-
cluding  cysts,  polycytic  disease,  harmartomas  or 
Wilm’s tumor can be present.  
Although parathyroid carcinomas are not a fea-
ture of multiple endocrine neoplasia type 1 (MEN 1), 
recently  10-11  parathyroid  carcinomas  have  been  de-
scribed in MEN 1. According to our Knowledge, only 
one case of parathyroid carcinoma has been reported 
in MEN 2 a syndrome 12.  
More than 90% of parathyroid carcinomas (PCA) 
are functional, and as such, the clinical features are 
due primarily to the effects of markedly elevated se-
rum  PTH  and  calcium  levels.  The  most  frequent 
complaints  are  weakness,  fatigue,  anorexia,  nausea, 
vomiting,  loss  of  weight,  dyspepsia,  constipation, 
headaches,  polydipsia  and  polyuria.  Bone,  joint, 
muscular  pain,  pathological  fractures,  and  renal 
stones  are  frequent  when  hyperparathyroid  state  is 
severe.  Recurrent  severe  pancreatitis,  anemia  and 
peptic ulcer disease can also occur. Among our 3 pa-
tients, 2 were symptomatic. One patient experienced 
fatigue,  ankle  and  knee  pain  and  the  other  fatigue, 
polyuria and polydipsia. 
 All those clinical signs are unspecific and often 
lead to a delayed diagnosis; furthermore even with a 
hypercalcaemia biologically proven, diagnosis may be 
missed. This was the case for all our patients before 
referral; all of them have been treated in the setting of 
a  longstanding  disease  with  a  tumor  size  ranging 
from 4.5 cm to 7 cm.  
A palpable mass in the neck is found in 30-76% 
of patients with parathyroid carcinoma 13. This clinical 
finding can help to differentiate between a benign and 
a malignant parathyroid disease; indeed fewer than 
5% of patients with benign disease have a palpable 
neck mass 14. The American national cancer data base 
15 confirmed in a report of 286 PCA a median size of 
3.3 cm. Despite this size, we would like to underline 
the fact that, due to intrathoracic localization, a pal-
pable mass was not found in 1 of our patients.  
Diagnosis 
Higher  serum  PTH and calcium levels than in 
parathyroid benign disease may be useful in the di-
agnosis of PCA. PTH levels higher than 300 pg/ml are 
indicator of potential malignant disease. In our pop-
ulation PTH level ranged from 642 to 1192pg/ml (N 
15-80pg/ml).  Iacobone  et  al  16  reminded  that  these 
high  values  should  be  considered  as  risk  factors  in 
individual patients. Owen et al 17 state that the pres-
ence of vocal cord palsy should alert the examiner of 
the possibility of cancer in a patient with hyperpara-
thyroidism. Thus, until proven otherwise, the patient 
should be considered to have a thyroid or parathyroid 
cancer. 
Ultrasound and tomography allow defining the 
extent of a neck mass. The ultrasound appearance of 
PCA is a hypo echoic soft tissue mass with irregular, 
poorly defined border and sign of invasion of adjacent 
structures  18.  Ultrasonography  (US)  revealed  neck 
mass in 2 patients, no signs of invasion was found. 
One PCA was located under the thyroid capsule and 
appeared  like  and  enlarged  thyroid  lobe,  the  other 
presented like a cystic mass at the inferior aspect of 
thyroid lobe. The latter located in the thorax was not 
detected on ultrasound. 
 Tomography Density measurements can assist 
in differentiating abnormal parathyroid tissues from 
lymph nodes and normal thyroid tissue 19.  
However, the only feature that may permit the 
preoperative diagnosis of parathyroid cancer is clear 
evidence  of  invasion  into  adjacent  tissue.  Tomogra-
phy was performed in one patient and demonstrated 
a cystic mass at the inferior aspect of the thyroid lobe 
(Fig 1).  
Differential diagnosis includes thyroid carcino-
ma and benign parathyroid disease 19.  
With a sensitivity of 91% MIBI scintigraphy may 
be a valid tool to assess the presence and localization 
of PCA. However, in a study dealing with 19 PCA 16, 
scintigraphy failed to localize mediastinal recurrences 
and pulmonary metastases. 
The patient with negative US underwent MIBI 
scintigraphy (Fig 3) which allowed us to localize an 
intra thoracic parathyroid carcinoma.  
Given  the  lack  of  reliable  factors  to  diagnose 
PCA, it is preferable to suspect it than fail to diagnose 
it because inadequate surgery leads to recurrences. 
Pathogenesis 
Over the last years the development and path-
ophysiology  of  parathyroid  carcinoma  has  become 
clearer. Oncogenes and tumor suppressor genes haves 
been  linked  to  parathyroid  carcinomas.  There  is  no  Journal of Cancer 2011, 2 
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definitive evidence of a primary role but altered ex-
pressions of these genes may play a part in the process 
of  malignant  transformation.  Five  genes  with  a  po-
tential role in malignancy have been identified and 
studied:  p53,  breast  carcinoma  susceptibility 
(BRCA2), cyclin D1/parathyroid adenomatosis gene 1 
(PRAD1), retinoblastoma tumor suppressor gene (RB) 
and  hyperparathyroidism  2  tumor  suppressor  gene 
(HRPT2)8. 
 The  HRPT2  gene  has  provided  the  best  evi-
dence.  This  gene  is  also  responsible  for  the  hy-
perparathyroidism  with  jaw-tumor  syndrome 
(HPT-JT).  PCA  occurs  with  higher  frequency  in 
HPT-JT patient than in sporadic PHHT (15% versus< 
1%) 20. HRPT2 may also play a role in the pathogene-
sis  of  sporadic  PCA.  Shattuck  et  al21  found  HPRT2 
mutation in 10 of 15 patients with sporadic PCA. 
The prevalence of HPRT2 mutation in sporadic 
PCA may  be as  high as 76.6%. Most mutations are 
nonsense forms leading to a lack or reduction of the 
encoded protein expression. HPRT2 encodes a protein 
called  parafibromin  (parathyroid  disease  and  fi-
bro-osseous  lesions)  which  is  a  tumor  suppressor 
protein.  Parafibromin  is  involved  in  the  cell  cycle 
regulation by inhibiting cell proliferation by blocking 
cyclin D1 expression. 
 Cyclin  D1  is  highly  expressed  in  parathyroid 
carcinomas, in a study by Vassef et al 22 91% (10/11) of 
PCA specimens were positive for cyclin D1 over ex-
pression compared with 39% (11/28) of the adenoma 
specimens. Cyclin D1 over expression may be a result 
of loos of parafibromin expression. 
Surgical management 
Even  by  experienced  surgeons,  up  to  86%  of 
PCA have been missed initially. The result is enuclea-
tion or piece meal resection, with the risk of tumor 
seeding in the operative field  15. Surgery is the only 
effective and curative treatment of PC; it should be 
performed as “en bloc” tumor resection with ipsilat-
eral thyroidectomy to avoid any capsular rupture. In 
the present report surgery had been undertaken un-
der  IV  methylene  blue  perfusion,  thus  obtaining  a 
better localization of the PC and allowing us a com-
plete  resection.  Kuriloff  23  et  al  demonstrate  that 
methylene  blue  facilitates  the  identification  of  ab-
normal parathyroid tissue in 97 % and a dark blue 
purple staining was observed in 89 %. Methylene blue 
helped to localize PC in our patients except the one 
located  beneath  the  thyroid  capsula.  This  condition 
allowed us to perform in each case an “en bloc“ re-
moval of the tumor. 
Intra operative (io) monitoring of intact PTH has 
proven  its  utility  in  predicting  cure  rate  in  benign 
hyperparathyroidy 24. Few studies address the issues 
of  ioPTH  monitoring  in  PCA.  Solorzano  et  al  25 
demonstrated, that after an “en bloc” removal of PCA, 
a drop of > 50% from baseline was predictive at least 6 
months of normocalcemia. Abdelgadir et al 26 reached 
the same results and conclude that ioPTH monitoring 
is accurate in predicting  normocalcemia after initial 
“en bloc” resection. 
Furthermore we believe that a significant drop 
(>50%) of ioPTH could be the reflection of an optimal 
surgery with “en bloc” resection of the lesion. PTH 
assay was undertaken just after surgery and strongly 
decreased in all patients ranging from 8 to 70 pg/ml. 
The management of recurrent or metastatic PC is 
primarily surgical 13. Recurrences in the neck should 
be treated with wide resection including the regional 
lymph  nodes.  Recent  data  demonstrated  that  omis-
sion  of  lymph  node  resection  carried  a  1.5-2-fold 
higher risk for recurrence and death at 5 days 27. 
All our patients underwent a central lymph node 
dissection; none of them had invaded lymph nodes. 
Distant metastasis should be excised if possible. 
Although resection of distant metastases or other foci 
of malignant tissue is rarely curative; their removal 
may result in a long period of normocalcemia, ranging 
from months to years 13. 
Pathology 
The differential diagnosis between parathyroid 
carcinoma  and  adenoma  is  difficult  for  the 
pathologist. Grossly, parathyroid carcinomas can be 
indistinguishable  from  adenomas.  They  are  usually 
present as larger masses that are adherent to adjacent 
structures, but these adherences are not diagnosed as 
periglandular  fibrosis  occasionally  occurs  in  adeno-
mas following haemorrhage 28, 29.  
Histologically,  a  definitive  diagnosis  of  malig-
nancy should be restricted to tumors displaying evi-
dence  of  vascular  invasion,  capsular  invasion  with 
growth into adjacent tissues, or metastases. As criteria 
for malignancy are mostly architectural and require 
adequate sampling, frozen sections are of little value. 
Criteria for vascular and capsular invasion are similar 
to those used in thyroid pathology: vascular invasion 
should  be  observed  in  the  capsule  or  in  the  sur-
rounding  soft  tissues  rather  than  inside  the  tumor. 
The presence of thick intratumoral fibrous bands is 
often regarded as a good indicator of malignancy but 
it is inconstant and not pathognomonic. Diffuse nu-
clear  enlargement  with  macronucleoli  suggests  ma-
lignancy. However, these atypia are only observed in 
2/3  of  carcinomas  and  focal  pleomorphism  is  com-
mon in adenomas 29, 17.   Journal of Cancer 2011, 2 
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Figure 1: Enhanced neck computed tomography showing a 
cystic mass (arrow) at the inferior aspect of the right thy-
roid lobe with a tracheal compression. 
 
Figure 2: Cystic mass (arrow) (5,5 x 3,5 x 3,5 cm) against 
the right thyroid lobe 
 
Figure 3: Preoperative MIBI isotopic scan disclosing a left 
anterior mediastinal captation 
 
Adjuvant therapy 
Two patients underwent radiotherapy (60-65gy) 
after  surgery  for  capsular  and  vascular  invasion. 
During irradiation time PTH level decreased from 119 
pg/ml  to  75  pg/ml  and  from  71  to  41  pg/ml  sug-
gesting  a  cytototoxic  effect  on  residual  tumor  cells. 
The  efficiency  of  radiation  therapy  in  parathyroid 
carcinoma remains controversial  30, 31, and radiother- Journal of Cancer 2011, 2 
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apy have been reported to be ineffective. The contro-
versy  stems  from  2  points.  Firstly,  the  first  studies 
performed with subjects with bulky neck disease who 
had  not  undergone  surgery,  have  failed  to  demon-
strate either a reduction in the mass of malignant tis-
sue or the attainment of normocalcemia. The common 
belief  is  that  radiation  therapy  does  not  result  in  a 
meaningful antitumor response 32, 33. Secondly, all the 
studies dealing with radiotherapy as adjuvant thera-
py include a small number of patients without any 
comparison, thus no strong conclusion can be drawn. 
The  M.D.  Anderson  group  treated  6  of  18  patients 
suffering from invasive parathyroid cancer with ad-
juvant radiotherapy in doses of 50 to 63 gy. Five of 6 
did not recur locally suggesting that radiation therapy 
could be effective in prevention of recurrence. A series 
from the mayo clinic reviewed 61 patients with PCA, 
57  underwent  en  bloc  surgery  alone  and  4  surgery 
with adjuvant radiotherapy. The 4 patients who re-
ceived adjuvant radiotherapy were alive with no re-
currences at 60 months whereas 25 patients (44%) had 
locoregional recurrence at a median time of 27 months 
after surgery. 
 Both  data  suggest  that  radiotherapy  could  be 
helpful as adjuvant therapy in preventing tumor re-
growth after surgery 35, 36. There is no consensus in the 
literature regarding the doses to be administered but 
these studies report doses ranging from 50 to 66 Gy. In 
the  present  report,  no  recurrence  occurred  2  and  4 
years after surgery. 
However, Prognosis is not predictable, because 
when malignancy is confirmed, recurrences occur in 
most case. The average time of recurrence is approx-
imately  3  years,  although  longer  intervals  up  to  20 
years have been reported 14.  
Conclusion 
PC is a very rare disease and probably an un-
der-diagnosed  pathology.  This  condition  leads  to  a 
delayed diagnosis when the tumor is already palpa-
ble.  
Patients  with  persistent  unexplained  hyper-
calcemia  should  undergo  a  complete  focusing  in-
cluding  neck  imaging  (US/CT/MRI)  and  MIBI  iso-
topic scan. In the setting of a suspected PC, neck ex-
ploration must be performed with an “en bloc” resec-
tion of the lesion with ipsi lateral thyroid lobectomy to 
avoid capsular rupture. A systematic central lymph 
node resection may improve outcomes in PC. 
Adjuvant  radiotherapy  appears  to  limit  tumor 
regrowth after surgery.  
Since recurrences up to 20 years have been de-
scribed, patients should undergo a life time follow up. 
Conflict of Interest 
The authors have declared that no conflict of in-
terest exists. 
References 
1.  Chiofalo MG, Scognamiglio F, Losito S, et al. Huge parathyroid 
carcinoma: clinical considerations and literature review. World 
Journal of surgical oncology 2005; 3:39. 
2.  Yuan S-F, Yan W, Ji G, Lv Y-G, Wang L. Surgical therapy of 
bilateral  parathyroid  carcinoma:  Report  of  an  unusual  case. 
EJSO 2010; 36: 107-109. 
3.  Ter Haar R W, Shen W T, Valk G D, Borel Rinkes I HM, Vriens 
M  R.  Parathyroid  Carcinoma,  a  Rare  Entity  with  Varying 
Presentation and Treatment. World Journal of Endocrine Sur-
gery 2010; 2(1): 33-36.  
4.  Obara T, Okamoto T, Kanbe M, Lihara M. Functioning para-
thyroid  carcinoma:  clinicopathologic  features  and  rational 
treatment. Semin Surg Oncol 1997; 13: 134-141. 
5.  Obara T, Fujimoto Y : Diagnosis and treatment of patients with 
parathyroid carcinoma. An update and review. World J Surg 
1991; 15: 738-744. 
6.  Lumachi F, Basso S.M.M, Basso U. Parathyroid Cancer: Etiolo-
gy, Clinical Presentation and Treatment. Anticancer Research 
2006; 26: 4803-4808.  
7.  Favia  G,  Lumachi  F,  Polistina  F,  D’Amico  DF.  Parathyroid 
carcinoma: sixteen new cases and suggestions for correct man-
agement. World J Surg 1998; 22: 1225-1230 
8.  Marcocci C, et al. Review: Parathyroid carcinoma. J Bone Min-
eral Res 2008; 23(12): 1869-1880. 
9.  Carpten JD, Robbins CM, Villablanca A, et al. HRPT2 encoding 
parafibromin,  is  mutated  in  hyperparathyroidism-jaw  tumor 
syndrome. Nat Genet. 2002 Dec;32(4):676-80.. 
10.  Dionisi  S,  Minisola  S,  Pepe  J,  et  al.  Concurrent  parathyroid 
adenomas and carcinoma in the setting of multiple endocrine 
neoplasia  type 1:  presentation  as  hypercalcemic crisis.  Mayo 
Clin Proc. 2002 Aug;77(8):866-9 
11.  Haven CJ, van Puijenbroek M, Tan MH, et al. Identification of 
MEN1  and  HRPT2  somatic  mutations  in  paraffin-embedded 
(sporadic) parathyroid carcinomas. Clin Endocrinol (Oxf). 2007 
Sep;67(3):370-6.  
12.  Jenkins PJ, Satta MA, Simmgen M, et al. Metastatic parathyroid 
carcinoma  in  the  MEN2A  syndrome.  Clin  Endocrinol  (Oxf). 
1997 Dec;47(6):747-51. 
13.  Shane  E.  Clinical  review  122:  Parathyroid  carcinoma.  J  Clin 
Endocrinol Metab 2001; 86: 485-493 
14.  Mittendorf EA, McHenry CR: Parathyroid carcinoma. Journal 
of Surgical Oncology 2005; 89: 136-142. 
15.  Hundahl SA, Fleming ID, Fremgen AM, et al. Two hundred 
eighty-six cases of parathyroid carcinoma treated in the U.S. 
between 1985-1995: a National Cancer Data Base Report. The 
American College of Surgeons Commission on Cancer and the 
American Cancer Society. Cancer. 1999 Aug 1;86(3):378-80.  
16.  Iacobone M, Lumachi F, Favia G. Up-to-date on parathyroid 
carcinoma: analysis of an experience of 19 cases. J Surg Oncol. 
2004 Dec 15;88(4):223-8. 
17.  Owen RP, Silver CE, Pellitteri PK, Shaha AR et al. Parathyroid 
carcinoma: A review. Head Neck 2011; 33: 429–436. 
18.  Daly BD, Coffey SL, Behan M. Ultrasonographic appearances of 
parathyroid carcinoma. Br J Radiol. 1989 Nov;62(743):1017-9. 
19.  Ernst O. Hyperparathyroidism: CT and MR findings. J Radiol. 
2009 Mar;90(3 Pt 2):409-12. 
20.  Howell VM, Haven CJ, Kahnoski K, et al. HRPT2 mutations are 
associated with malignancy in sporadic parathyroid tumours. J 
Med Genet. 2003 Sep;40(9):657-63.   Journal of Cancer 2011, 2 
 
http://www.jcancer.org 
537 
21.  Shattuck TM, Välimäki S, Obara T, et al. Somatic and germ-line 
mutations of  the HRPT2  gene  in  sporadic  parathyroid  carci-
noma. N Engl J Med. 2003 Oct 30;349(18):1722-9. 
22.  Vasef MA, Brynes RK, Sturm M, et al. Expression of cyclin D1 in 
parathyroid carcinomas, adenomas, and hyperplasias: a paraf-
fin  immunohistochemical  study.  Mod  Pathol.  1999 
Apr;12(4):412-6 
23.  Kuriloff DB, Sanborn KV. Rapid intraoperative localization of 
parathyroid  glands  utilizing  methylene  blue  infusion.  Oto-
laryngol Head Neck Surg. 2004 Nov;131(5):616-22. 
24.  Irvin GL 3rd, Solorzano CC, Carneiro DM. Quick intraoperative 
parathyroid hormone assay: surgical adjunct to allow limited 
parathyroidectomy, improve success rate, and predict outcome. 
World J Surg. 2004 Dec;28(12):1287-92. 
25.  Solórzano CC, Carneiro-Pla DM, Lew JI, et al. Intra-operative 
parathyroid hormone monitoring in patients with parathyroid 
cancer. Ann Surg Oncol. 2007 Nov;14(11):3216-22. 
26.  Abdelgadir Adam M, Untch BR, Olson JAJr. Parathyroid car-
cinoma: current understanding and new insights into gene ex-
pression  and  intraoperative  parathyroid  hormone  kinetics. 
Oncologist. 2010;15(1):61-72.  
27.  Schulte KM, Talat N, Miell J, Moniz C, Sinha P, Diaz-Cano S. 
Lymph node involvement and surgical approach in parathy-
roid cancer. World J Surg. 2010 Nov;34(11):2611-20. 
28.  Levin KE, Galante M, Clark OH. Parathyroid carcinoma versus 
parathyroid  adenoma  In  patients  with  profound  hypercalce-
mia. Surgery. 1987 Jun;101(6):649-60 
29.  Bondeson L, Grimelius L, deLellis RA, et al. Parathyroid carci-
noma. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, Eds. Tu-
mours of endocrine organs. Lyon: IARCPress. 2004: 128-32. 
30.  Wynne AG, van Heerden J, Carney JA, Fitzpatrick LA. Para-
thyroid carcinoma: clinical and pathologic features in 43 pa-
tients. Medicine (Baltimore). 1992 Jul;71(4):197-205.  
31.  Sandelin  K,  Auer  G, Bondeson L,  Grimelius  L,  Farnebo  LO. 
Prognostic factors in parathyroid cancer: a review of 95 cases. 
World J Surg. 1992;16(4):724-31 
32.  Chow  E,  Tsang  RW,  Brierley  JD,  et  al.  Parathyroid  carcino-
ma--the  Princess  Margaret  Hospital  experience.  Int  J  Radiat 
Oncol Biol Phys. 1998 Jun 1;41(3):569-72. 
33.  Fujimoto Y, Obara T, Ito Y, et al. Surgical treatment of ten cases 
of parathyroid carcinoma: importance of an initial en bloc tu-
mor resection. World J Surg. 1984 Jun;8(3):392-400 
34.  Holmes EC, Morton DL, Ketcham AS. Parathyroid carcinoma: a 
collective review. Ann Surg. 1969 Apr;169(4):631-40.  
35.  Munson ND, Foote RL, Northcutt RC et al. Parathyroid carci-
noma: is there a role for adjuvant radiation therapy? Cancer. 
2003 Dec 1;98(11):2378-84. 
36.  Rasmuson  T,  Kristoffersson  A,  Boquist  L.  Positive  effect  of 
radiotherapy  and  surgery  on  hormonally  active  pulmonary 
metastases of primary parathyroid carcinoma. Eur J Endocrinol. 
2000 Dec;143(6):749-54 
 
 